Search results
Results from the WOW.Com Content Network
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.
The targets and drugs in TTD cover 583 protein biochemical classes and 958 drug therapeutic classes, respectively. [1] The latest version of the International Classification of Diseases (ICD-11) codes released by WHO are incorporated in TTD to facilitate the clear definition of disease/disease class.
Current Drug Metabolism; Current Opinion in Pharmacology; Current Pharmaceutical Design; Current Trends in Biotechnology and Pharmacy; DARU Journal of Pharmaceutical Sciences; Drug Delivery; Drug Design, Development and Therapy; Drug Development and Industrial Pharmacy; Drug Discovery Today; Drug, Healthcare and Patient Safety; Drug Safety ...
Bentham Science Publishers is a company that publishes scientific, technical, and medical journals and e-books.It publishes over 120 subscription-based academic journals [1] and around 40 open access journals.
move to sidebar hide. From Wikipedia, the free encyclopedia
Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier.It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.
Drug Target Insights is a peer-reviewed open access academic journal focusing on drug treatment targets and clinical therapeutics. The journal was founded in 2006 by Monica Milani and is currently edited by Giulio Zuanetti.
Journal of Drug Targeting is a peer-reviewed medical journal published by Informa that covers research on all aspects of drug delivery and drug targeting for molecular and macromolecular drugs. The editor in chief is Saghir Akhtar (College of Medicine, Qatar University ).